Lacticaseibacillus rhamnosus AFY01 and application of product prepared from lacticaseibacillus rhamnosus AFY01 in inflammatory colon cancer
US12398366B1 · kind B1 · utility
Assignee
Inventors
Key dates
| Filing date | Jan 15, 2025 |
| Grant date | Aug 26, 2025 |
| Priority date | — |
| Expiry date | Jan 15, 2045 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N1/205
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Lacticaseibacillus rhamnosus AFY01 and an application of a product prepared from Lacticaseibacillus rhamnosus AFY01 in inflammatory colon cancer are provided, which relates the field of microbes. A preservation number of the Lacticaseibacillus rhamnosus AFY01 is CGMCC No. 27362. The Lacticaseibacillus rhamnosus AFY01 can effectively alleviate weight loss, intestinal inflammation and edema induced colon shortening in mice with colon cancer, reduce colon coefficient, visceral index and incidence of intestinal tumors in mice, improve intestinal inflammation, promote apoptosis of intestinal tumor cells to slow down the development of colon cancer. The Lacticaseibacillus rhamnosus AFY01 expands bacterial resources to provide technical support for the prevention and treatment of colorectal cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.